NVO

Novo Nordisk stock plunged nearly 15% following its earnings report. The profit decline is likely attributed to increased marketing spend and competitive pressures in the weight-loss drug market. Investors are reassessing future growth prospects.

AI-generated: summaries written by AI from the linked sources. How we use AI